Focus: Catapult Therapeutics is a private Dutch biotech founded in 2015 specializing in antibody therapy and cell-based therapeutics for oncology and respiratory diseases. The company operates at early clinical stage with a small, focused pipeline of immunotherapy programs.
Profile data last refreshed 15m ago · AI intelligence enriched 2w ago
Stable — net -1 jobs in 30d
2 added, 3 removed. Backfill posture.
Catapult is a high-risk, early-stage cell therapy play best suited to scientists willing to accept liquidity and operational uncertainty in exchange for deep technical involvement in novel immunotherapy.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Catapult Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Catapult Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo